The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Marcel Levi

Marcel Levi

MD, Dept. Internal Medicine (F-4)

Academic Medical Center



Name/email consistency: high



  • Marcel Levi, MD, Dept. Internal Medicine (F-4), Academic Medical Center, E-mail:. 2012
  • Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands. 1999 - 2011
  • Center for Hemostasis, Thrombosis, Atherosclerosis and Inflammation Research, Laboratory of Experimental Medicine, Netherlands. 1998 - 1999


  1. Reverse engineering for new oral anticoagulants: Non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban. Levi, M. Thromb. Haemost. (2012) [Pubmed]
  2. Factor v Leiden mutation in severe infection and sepsis. Levi, M., Schouten, M., van't Veer, C., van der Poll, T. Semin. Thromb. Hemost. (2011) [Pubmed]
  3. Treatment with recombinant human activated protein C: one size does not fit all. Levi, M. Crit. Care (2011) [Pubmed]
  4. Adequate thromboprophylaxis in critically ill patients. Levi, M. Crit. Care (2010) [Pubmed]
  5. Safety of recombinant activated factor VII in randomized clinical trials. Levi, M., Levy, J.H., Andersen, H.F., Truloff, D. N. Engl. J. Med. (2010) [Pubmed]
  6. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Levi, M.M., Eerenberg, E., Löwenberg, E., Kamphuisen, P.W. Neth. J. Med (2010) [Pubmed]
  7. Inflammation and coagulation. Levi, M., van der Poll, T. Crit. Care Med. (2010) [Pubmed]
  8. The coagulant response in sepsis and inflammation. Levi, M. Hamostaseologie (2010) [Pubmed]
  9. Emergency reversal of antithrombotic treatment. Levi, M. Intern. Emerg. Med (2009) [Pubmed]
  10. Use of recombinant factor VIIa in the perioperative period. Levi, M. Hamostaseologie (2009) [Pubmed]
  11. Epidemiology and management of bleeding in patients using vitamin K antagonists. Levi, M. J. Thromb. Haemost. (2009) [Pubmed]
  12. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Levi, M., Hobbs, F.D., Jacobson, A.K., Pisters, R., Prisco, D., Bernardo, A., Haas, M., Heidrich, J., Rosenberg, M., Nielsen, J.D., Wuillemin, W.A. Semin. Thromb. Hemost. (2009) [Pubmed]
  13. Management strategies for optimal control of anticoagulation in patients with atrial fibrillation. Levi, M., de Peuter, O.R., Kamphuisen, P.W. Semin. Thromb. Hemost. (2009) [Pubmed]
  14. Metabolic modulation of inflammation-induced activation of coagulation. Levi, M., Nieuwdorp, M., van der Poll, T., Stroes, E. Semin. Thromb. Hemost. (2008) [Pubmed]
  15. Self-management of anticoagulation. Levi, M. Expert. Rev. Cardiovasc. Ther (2008) [Pubmed]
  16. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Levi, M., Hovingh, G.K., Cannegieter, S.C., Vermeulen, M., Büller, H.R., Rosendaal, F.R. Blood (2008) [Pubmed]
  17. The inflammation-coagulation axis as an important intermediate pathway in acute lung injury. Levi, M., Schultz, M. Crit. Care (2008) [Pubmed]
  18. Fibrophilia: a new disease entity?. Levi, M., Dik, K. J. Thromb. Haemost. (2008) [Pubmed]
  19. Activated protein C in sepsis: a critical review. Levi, M. Curr. Opin. Hematol. (2008) [Pubmed]
  20. The coagulant response in sepsis. Levi, M. Clin. Chest Med. (2008) [Pubmed]
  21. Thrombocytopenia in critically ill patients. Levi, M., Löwenberg, E.C. Semin. Thromb. Hemost. (2008) [Pubmed]
  22. The role of natural anticoagulants in the pathogenesis and management of systemic activation of coagulation and inflammation in critically ill patients. Levi, M., van der Poll, T. Semin. Thromb. Hemost. (2008) [Pubmed]
  23. Bleeding complications in patients on anticoagulants who would have been disqualified for clinical trials. Levi, M., Hovingh, K. Thromb. Haemost. (2008) [Pubmed]
  24. Sepsis, coagulation, and antithrombin: old lessons and new insights. Levi, M., Schouten, M., van der Poll, T. Semin. Thromb. Hemost. (2008) [Pubmed]
  25. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Levi, M., Levy, M., Williams, M.D., Douglas, I., Artigas, A., Antonelli, M., Wyncoll, D., Janes, J., Booth, F.V., Wang, D., Sundin, D.P., Macias, W.L. Am. J. Respir. Crit. Care Med. (2007) [Pubmed]
  26. Clinical relevance of the effects of plasma expanders on coagulation. Levi, M., Jonge, E. Semin. Thromb. Hemost. (2007) [Pubmed]
  27. Disseminated intravascular coagulation. Levi, M. Crit. Care Med. (2007) [Pubmed]
  28. Recombinant factor VIIa and trauma: treatment that does not leave you in the cold. Levi, M. J. Thromb. Haemost. (2007) [Pubmed]
  29. Recombinant human activated protein C: current insights into its mechanism of action. Levi, M., van der Poll, T. Crit. Care (2007) [Pubmed]
  30. Plasma and plasma components in the management of disseminated intravascular coagulation. Levi, M., de Jonge, E., van der Poll, T. Best. Pract. Res. Clin. Haematol (2006) [Pubmed]
  31. Tissue factor in infection and severe inflammation. Levi, M., van der Poll, T., ten Cate, H. Semin. Thromb. Hemost. (2006) [Pubmed]
  32. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. Levi, M., Choi, G., Picavet, C., Hack, C.E. J. Allergy Clin. Immunol. (2006) [Pubmed]
  33. Genetic variation in basal and endotoxin-induced tissue factor expression in vivo. Levi, M. J. Thromb. Haemost. (2006) [Pubmed]
  34. Coagulation abnormalities in critically ill patients. Levi, M., Opal, S.M. Crit. Care (2006) [Pubmed]
  35. Disseminated intravascular coagulation: What's new?. Levi, M. Crit. Care. Clin (2005) [Pubmed]
  36. New antithrombotics in the treatment of thromboembolic disease. Levi, M. Eur. J. Intern. Med. (2005) [Pubmed]
  37. Platelets in sepsis. Levi, M. Hematology (2005) [Pubmed]
  38. Platelets. Levi, M. Crit. Care Med. (2005) [Pubmed]
  39. Antithrombin in sepsis revisited. Levi, M. Crit. Care (2005) [Pubmed]
  40. Current understanding of disseminated intravascular coagulation. Levi, M. Br. J. Haematol. (2004) [Pubmed]
  41. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Levi, M., de Jonge, E., van der Poll, T. Ann. Med. (2004) [Pubmed]
  42. Coagulation in sepsis: all bugs bite equally. Levi, M., van der Poll, T. Crit. Care (2004) [Pubmed]
  43. Critical bleeding in surgery: conventional therapy and new prospects. Levi, M. Minerva. Anestesiol (2004) [Pubmed]
  44. Bidirectional relation between inflammation and coagulation. Levi, M., van der Poll, T., Büller, H.R. Circulation (2004) [Pubmed]
  45. Recombinant factor VIIa: a general hemostatic agent? Not yet. Levi, M. J. Thromb. Haemost. (2004) [Pubmed]
  46. Platelets at a crossroad of pathogenic pathways in sepsis. Levi, M. J. Thromb. Haemost. (2004) [Pubmed]
  47. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Levi, M., Dörffler-Melly, J., Reitsma, P., Buller, H., Florquin, S., van der Poll, T., Carmeliet, P. Blood (2003) [Pubmed]
  48. All heparins are equal, but some are more equal than others. Levi, M. J. Thromb. Haemost. (2003) [Pubmed]
  49. Measuring activated protein C in plasma to assess its role as a critical modulator of coagulation and inflammation. Levi, M. J. Thromb. Haemost. (2003) [Pubmed]
  50. Haemostasis and thrombosis: new developments in treatment strategies. Levi, M. Neth. J. Med (2003) [Pubmed]
  51. Therapeutic options in patients with DIC and cancer. Levi, M. Pathophysiol. Haemost. Thromb. (2003) [Pubmed]
  52. Infection and inflammation and the coagulation system. Levi, M., Keller, T.T., van Gorp, E., ten Cate, H. Cardiovasc. Res. (2003) [Pubmed]
  53. Prevention and treatment of bleeding by pro-hemostatic treatment strategies. Levi, M., Vink, R., de Jonge, E. Wien. Med. Wochenschr (2003) [Pubmed]
  54. Sepsis and disseminated intravascular coagulation. Levi, M., de Jonge, E., van der Poll, T. J. Thromb. Thrombolysis (2003) [Pubmed]
  55. Cancer and thrombosis. Levi, M. Clin. Adv. Hematol. Oncol (2003) [Pubmed]
  56. The diagnosis of disseminated intravascular coagulation. Levi, M., de Jonge, E., Meijers, J. Blood Rev. (2002) [Pubmed]
  57. Therapeutic intervention in disseminated intravascular coagulation: have we made any progress in the last millennium?. Levi, M., de Jonge, E., van der Poll, T. Blood Rev. (2002) [Pubmed]
  58. Advances in the understanding of the pathogenetic pathways of disseminated intravascular coagulation result in more insight in the clinical picture and better management strategies. Levi, M., de Jonge, E., van der Poll, T., ten Cate, H. Semin. Thromb. Hemost. (2001) [Pubmed]
  59. Usefulness and limitations of animal models of venous thrombosis. Levi, M., Dörffle-Melly, J., Johnson, G.J., Drouet, L., Badimon, L. Thromb. Haemost. (2001) [Pubmed]
  60. Cancer and DIC. Levi, M. Haemostasis (2001) [Pubmed]
  61. Disseminated intravascular coagulation. Levi, M., Ten Cate, H. N. Engl. J. Med. (1999) [Pubmed]
  62. Disseminated intravascular coagulation. Levi, M., de Jonge, E., van der Poll, T., ten Cate, H. Thromb. Haemost. (1999) [Pubmed]
  63. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Levi, M., Cromheecke, M.E., de Jonge, E., Prins, M.H., de Mol, B.J., Briët, E., Büller, H.R. Lancet (1999) [Pubmed]
  64. Fibrinogen-coated albumin microcapsules reduce bleeding in severely thrombocytopenic rabbits. Levi, M., Friederich, P.W., Middleton, S., de Groot, P.G., Wu, Y.P., Harris, R., Biemond, B.J., Heijnen, H.F., Levin, J., ten Cate, J.W. Nat. Med. (1999) [Pubmed]
  65. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Levi, M., van Der POLL, T., ten CATE, H., Kuipers, B., Biemond, B.J., Jansen, H.M., ten CATE, J.W. Am. J. Respir. Crit. Care Med. (1998) [Pubmed]
WikiGenes - Universities